Pharma in China and India: Market-Specific Social Risks and Opportunities

Emerging markets are increasingly pivotal in the growth of the pharmaceutical industry. Pharmaceutical companies operating in these markets, whether global or domestic players, are exposed to market-specific social risks that affect public health and may also pose material financial risks.

Sustainalytics and guests discussed the material social risks facing both global and local players in the pharmaceuticals industry. The discussion focused mainly on operations in China and India, which are key growth markets for the industry. Panelists also discussed the opportunities market shifts could afford forward looking companies to not only increase their market share, but also become industry ESG leaders. 

The panelists included:

  • Lloyd Kurtz, Chief Investment Officer, Nelson Capital Management (Session l)
  • Jaysaree Iyer, Head of Research, Access to Medicine (Session ll)
  • Hazel Goedhart, Associate Analyst, Sustainalytics
Session I*Session II

Please send any questions or comments about the presentations above to communications@sustainalytics.com.

The subject of these webinars was based on Sustainalytics' report Pharma in China and India: Market-Specific Social Risks and Opportunities. Follow the link to download the full report.